On-site inspection by the Japan Fair Trade Commission over suspected violations of the Antimonopoly Act
First written in FY2024. 1 of 2 entries say "Materialised", first in FY2024. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026MitigatedAnnual report
「The Company was investigated by the Japan Fair Trade Commission over suspected violations of the Antimonopoly Act, and the commitment plan submitted by the Company under the Act was approved in February 2025. The Company is currently implementing the commitment plan steadily. This approval does not constitute a finding that the Company violated the Antimonopoly Act.」
Disclosed that, following the 2024 on-site inspection, the commitment plan submitted by the Company was approved in February 2025 and is being implemented. Also explained that the approval did not constitute a finding of a violation. - FY2024MaterialisedAnnual report
「In addition, on 4 June 2024, the Company was subject to an on-site inspection by the Japan Fair Trade Commission on suspicion of violating the Antimonopoly Act, including tied sales, in transactions involving blood coagulation analyzers and reagents in the Japanese market, specifically reagents for measuring FDP and reagents for measuring D-dimer. The Company will continue to cooperate fully with the Japan Fair Trade Commission's inspection.」
Disclosed that the Company had been subject to an on-site inspection by the Japan Fair Trade Commission over suspected violations of the Antimonopoly Act in transactions involving blood coagulation analyzers and reagents.